Epigenetics Market size was valued at USD 1.6 billion in 2023 to USD 4.7 billion by 2031, growing at a CAGR of 14.8% in the forecast period (2024-2031). The demand for epigenetics market is increasing exponentially due to the vital part epigenetics play in analysing gene regulation apart from DNA sequencing. It also helps in researching about various diseases and advancing personalized medicines. The market leaders and startups operating in this sector are cumulatively investing for advancing the epigenetic domain. Epigenetics refers to the investigation of transformations in heritable phenotype that happens without any changes to the DNA sequencing.
The growing application of epigenetics is also boosting the growth of the market. Moreover, increasing cardiovascular diseases, cancer, and genetic disorders along with improved research and development activities in DND sequencing are supporting the market growth. Furthermore, the growing aging population in various nations is positively influencing the development of the epigenetics market. Epigenetics drugs are utilized to prevent various enzymes like HDMs, HMTs, DNMTs, HATs, and HDACs, in epigenetic disorders. They can efficiently function with other therapies, like immunotherapy or chemotherapy. The growing incidences of cancer along with the rising emphasis of market leaders to treat cancer and other diseases, the market will continuously witness significant growth.
Request your free sample PDF of the report today: https://www.skyquestt.com/sample-request/epigenetics-market
Increasing Research and Development to Improve Drug Discovery
Recently, the epigenetic modifications are gaining recognition as it is prooving to be extremely useful targets for drug discovery, which is propelling the market growth. Pharmaceutical companies have started heavily investing in epigenetic research for developing advanced therapies. In cancer treatment, drugs like Azacitidine and Decitabine, which target DNA methylation, have bought immense evolution in the therapy options, highlighting the capability of the market. Furthermore, constant research into epigenetic therapies that can be used for neurological disorders and autoimmune diseases is also further progressing and advancing the market.
Growing Personalized Medicine and Drug Development to Develop Precise Treatment for Cancer
The profiling of epigenetic helps personalized medicine to customize treatments according to the patient’s unique epigenetic profile. This method is extremely vital in advancing targeted therapies and drug discovery. This is boosting the adoption of epigenetic technologies by pharmaceutical and biotechnology firms. In oncology, epigenetic markers are helping in the development of accurate cancer treatments, enhancing the efficiency and patient outcomes. This growing emphasis on personalized therapies is immensely contributing to the growth of epigenetics market.
In December 2023, BioLabs extended their joint venture with Promega. This joint initiavtive will help in increasing the speed of life sciences innovation worldwide by supporting early-stage startups.
In November 2023, QIAGEN strategically collaborated with Element Biosciences, Inc. This will help them in offering a wide range of NGS workflows for the advanced Element AVITI System.
In October 2023, Zenith Epigenetics Ltd. engaged into an agreement with Cencora for commercializing the ZEN-3694 program. It is an advanced process for improving the efficieny of treating cancer of presently marketed drugs.
For a tailored report, contact us to request a free customization: https://www.skyquestt.com/speak-with-analyst/epigenetics-market
This Market Consist of the Following Segments
Product Type
Reagents
Kits
Instruments
Enzymes
Technology
DNA Methylation
Histone Methylation
Histone Acetylation
MicroRNA Modification
Other Epigenetic Modifications
Application
Oncology
Cardiovascular Diseases
Metabolic Diseases
Neurological Disorders
Immunology
Top Player’s Company Profiles
AbbVie Inc.
AstraZeneca PLC
Bayer AG
BeiGene Ltd.
Bristol Myers Squibb Company
Epizyme, Inc.
GlaxoSmithKline PLC
Incyte Corporation
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Roche Holding AG
Seattle Genetics, Inc.
Takeda Pharmaceutical Company Limited
Targovax, Inc.
Vertex Pharmaceuticals Incorporated
Vivid Biosciences Inc.
Zymeworks Inc.
Purchase now to gain valuable insights and stay informed: https://www.skyquestt.com/buy-now/epigenetics-market
Incorporation of Epigenetics with Omics Technologies to Better Understand Biological Systems
The incorporation of epigenetics with other omics technologies, like genomics and proteomics, improves the understanding of biological systems. This is increasing the demand for multi-omics platforms, boosting the market growth. Furthermore, by combining epigenetic data with genomic and transcriptomic data helps the researchers to analyze the complex gene regulatory networks. This helps in better understanding the diseases and drug development, further progressing the market forward.
To read the full report, please visit: https://www.skyquestt.com/report/epigenetics-market
Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/epigenetics-market